Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From May 2019 to May 2024
Tamara L. Joseph Named General Counsel of TKT
CAMBRIDGE, Mass., Feb. 15 /PRNewswire-FirstCall/ -- Transkaryotic Therapies,
Inc. (NASDAQ:TKTX) today announced that Tamara L. Joseph has joined the company
as Vice President, General Counsel. Ms. Joseph has broad legal experience in
the pharmaceutical industry, including 16 years of experience in the US, France
and Belgium. She joins TKT from Biogen Idec where she served as Vice
President, International Legal. In her role as General Counsel at TKT, Ms.
Joseph will have responsibility for all its legal and government relations
activities.
"I am confident that Tamara's knowledge, judgment and integrity will be
important assets for TKT," said Michael J. Astrue, President and Chief
Executive Officer. "In addition, her broad experience within the
pharmaceutical industry will be extremely beneficial to us as we continue to
bring new products to market over the next several years."
While at Biogen Idec, Ms. Joseph had overall responsibility for the
international legal and public affairs functions, advising senior management on
international legal issues. She was also an Associate at the law offices of
Morrison & Foerster in New York, Los Angeles and Brussels, where she handled
litigation, intellectual property, and commercial law matters. Prior to
joining Morrison & Foerster, Ms. Joseph was an Associate at Fried, Frank,
Harris, Shriver & Jacobson in New York. She received a B.A. from Duke
University, a J.D. from the University of Michigan Law School, and LLM degrees
from the College of Europe and from the University of Paris. She is admitted
to practice law in New York, California, England and Wales.
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily focused
on researching, developing and commercializing treatments for rare diseases
caused by protein deficiencies. Within this focus, the company markets
Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease. In addition to
its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease, in
the European Union. TKT was founded in 1988 and is headquartered in Cambridge,
Massachusetts, with additional operations in Europe, Canada and South America.
Additional information about TKT is available on the company's website at
http://www.tktx.com/.
This press release contains forward-looking statements regarding TKT's
management structure, as well as statements containing the words "believes,"
"anticipates," "plans," "expects," "estimates," "intends," "should," "could,"
"will," "may," and similar expressions. There are a number of important
factors that could cause the company's actual results to differ materially from
those indicated by such forward-looking statements, including, whether TKT will
be able to successfully manage its legal and business development functions,
and other factors set forth under the caption "Certain Factors Which May Affect
Future Results" in the company's Quarterly Report on Form 10- Q for the quarter
ended September 30, 2004, which is on file with the Securities and Exchange
Commission and are incorporated herein by reference. While the company may
elect to update forward-looking statements at some point in the future, the
company specifically disclaims any obligation to do so, even if its
expectations change.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a trademark of
Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of Sanofi-Aventis SA.
For More Information Contact:
Justine E. Koenigsberg
Senior Director, Corporate Communications
(617) 349-0271
Daniella M. Lutz
Corporate Communications Manager
(617) 349-0205
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
http://photoarchive.ap.org/
DATASOURCE: Transkaryotic Therapies, Inc.
CONTACT: Justine E. Koenigsberg, Senior Director, Corporate
Communications, +1-617-349-0271, or Daniella M. Lutz, Corporate Communications
Manager, +1-617-349-0205 both of Transkaryotic Therapies, Inc.
Web site: http://www.tktx.com/
Company News On-Call: http://www.prnewswire.com/comp/120657.html